查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1607170

全球基因融合測試市場：按技術、適應症、應用和最終用戶分類 - 2025-2030 年預測

Gene Fusion Testing Market by Technique (Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Nanostring), Indication (Haematological Malignacies, Solid Tumors), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年基因融合測試市值為4.2834億美元，預計到2024年將達到4.8095億美元，複合年成長率為12.40%，預計到2030年將達到9.7134億美元。

基因融合測試在精準醫學中極為重要，其中使用先進的定序技術來識別基因變化。基因融合測試透過檢測導致腫瘤形成和遺傳異常的基因重排，在癌症和其他遺傳疾病的診斷和製定治療計劃中發揮著至關重要的作用。癌症盛行率的不斷增加以及對透過根據個人基因譜量身定做醫療干預措施來提高治療效果的標靶治療的需求推動了對基因融合測試的需求。基因融合測試廣泛應用於臨床腫瘤學、基因研究和個人化醫療，最終用戶範圍從醫院、診斷實驗室到學術和研究機構。市場成長受到基因組研究投資增加、次世代定序技術進步以及對精準醫學治療日益接受的影響。潛在的機會包括非腫瘤領域的擴大應用、高性能篩檢的技術進步以及分子診斷測試的監管要求。然而，測試成本高、測試通訊協定缺乏標準化以及複雜的報銷環境等挑戰阻礙了市場的擴張。由於技術障礙以及需要熟練專家解釋結果，他們也面臨限制。利用創新並加速研究，專注於具有成本效益且易於使用的診斷平台，整合人工智慧進行資料解釋，以及與生物技術公司合作增強技術將有助於業務成長的有效途徑。市場是動態的，技術進步和不斷變化的監管環境共同推動市場。在資料分析和方便用戶使用的測試解決方案方面進行創新的公司最有能力利用當前的勢頭。透過與醫療保健提供者持續合作的回饋和改進也將推動這一領域的發展，並可以提高治療的臨床相關性和有效性。

主要市場統計
基準年[2023] 4.2834億美元
預計年份 [2024] 48095萬美元
預測年份 [2030] 97134萬美元
複合年成長率（%） 12.40%

市場動態：揭示快速發展的基因融合測試市場的關鍵市場洞察

供需的動態交互作用正在改變基因融合測試市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球癌症盛行率上升
    • 基因組和分子生物學研究的增加
    • 廣泛用於生物標記發現
  • 市場限制因素
    • 基因融合測試高成本且機會有限
  • 市場機會
    • 液態切片基因融合檢測技術的出現
    • 個人化醫療和標靶治療的趨勢
  • 市場問題
    • 嚴格的法規和缺乏熟練的專業人員

波特五力：駕馭基因融合測試市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解基因融合檢測市場的外部影響

外部宏觀環境因素在塑造基因融合檢測市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解基因融合檢測市場的競爭狀況

對基因融合測試市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣：基因融合測試市場供應商績效評估

FPNV定位矩陣是評估基因融合測試市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製基因融合測試市場的成功之路

基因融合測試市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3. 塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的癌症發生率正在上升
      • 基因組和分子生物學研究的增加
      • 廣泛用於生物標記發現
    • 抑制因素
      • 獲得基因融合測試的費用昂貴且有限
    • 機會
      • 液態生物檢體基因融合檢測技術的出現
      • 個人化醫療和標靶治療的趨勢
    • 任務
      • 嚴格的法規和缺乏熟練的專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 基因融合測試市場：依技術分類

  • 介紹
  • 螢光雜合反應螢光（FISH）
  • 免疫組織化學 (IHC)
  • 奈米線
  • NGS擴增子
  • 逆轉錄聚合酵素鏈鎖反應(RT-PCR)

第7章 基因融合測試市場：依適應症分類

  • 介紹
  • 骨髓惡性腫瘤
  • 固態腫瘤

第8章 基因融合測試市場：依應用分類

  • 介紹
  • 疾病診斷
  • 研究

第9章 基因融合測試市場：依最終用戶分類

  • 介紹
  • 學術研究中心
  • 醫院和診斷實驗室
  • 製藥和生物技術公司

第10章 北美、南美基因融合檢測市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太基因融合檢測市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東、非洲基因融合檢測市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議

公司名單

  • Amoy Diagnostics Co., Ltd.
  • Arima Genomics, Inc.
  • Biocare Medical, LLC
  • Biocartis NV
  • Caris Life Sciences
  • Danaher Corporation
  • Empire Genomics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.
  • OncoDNA SA
  • Paragon Genomics, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated.
  • SOPHiA GENETICS SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-2E76C3E47FBF

The Gene Fusion Testing Market was valued at USD 428.34 million in 2023, expected to reach USD 480.95 million in 2024, and is projected to grow at a CAGR of 12.40%, to USD 971.34 million by 2030.

Gene fusion testing is critical in the precision medicine landscape, identifying genetic alterations through advanced sequencing techniques. It plays a pivotal role in diagnosing and developing treatment plans for cancer and other genetic disorders by detecting gene rearrangements that can drive tumorigenesis or genetic malfunctions. The necessity of gene fusion testing is driven by the increasing incidence of cancer and the demand for targeted therapies, which enhance treatment efficacy by tailoring medical interventions to individual genetic profiles. It is applied extensively in clinical oncology, genetic research, and personalized medicine, with end-users ranging from hospitals and diagnostic laboratories to academic and research institutions. Market growth is influenced by rising investments in genomic research, advancements in next-generation sequencing technologies, and the growing acceptance of precision medicine treatments. Potential opportunities include expanding applications in non-oncology segments, technological advancements in high-throughput screening, and regulatory mandates for molecular diagnostic tests. However, challenges such as high testing costs, a lack of standardization in test protocols, and complex reimbursement environments hinder market expansion. The market faces limitations posed by technological barriers and the necessity for skilled professionals to interpret results. To leverage innovation and foster research, focusing on cost-effective and easy-to-use diagnostic platforms, artificial intelligence integration for data interpretation, and partnerships with biotechnology firms for technique enhancement are viable pathways for business growth. The market is dynamic, driven by both technological advancements and evolving regulatory landscapes. Companies poised to innovate in data analytics and user-friendly testing solutions are best positioned to capitalize on the current momentum. Continuous collaboration with healthcare providers for feedback and improvements could also drive the sector towards achieving greater clinical relevance and efficacy in medical treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 428.34 million
Estimated Year [2024] USD 480.95 million
Forecast Year [2030] USD 971.34 million
CAGR (%) 12.40%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Fusion Testing Market

The Gene Fusion Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer worldwide
    • Increasing genomic and molecular biology reserach
    • Extensive use for discovery of biomarkers
  • Market Restraints
    • High cost and limited accessibility to gene fusion testing
  • Market Opportunities
    • Advent of liquid-biopsy based gene fusion testing technologies
    • Inclination towards personalize medicine and targeted therapies
  • Market Challenges
    • Stringent regulations and dearth of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Gene Fusion Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Fusion Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Fusion Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Fusion Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Fusion Testing Market

A detailed market share analysis in the Gene Fusion Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Fusion Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Fusion Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gene Fusion Testing Market

A strategic analysis of the Gene Fusion Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gene Fusion Testing Market, highlighting leading vendors and their innovative profiles. These include Amoy Diagnostics Co., Ltd., Arima Genomics, Inc., Biocare Medical, LLC, Biocartis NV, Caris Life Sciences, Danaher Corporation, Empire Genomics, Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Myriad Genetics, Inc., Natera, Inc., NeoGenomics, Inc., OncoDNA SA, Paragon Genomics, Inc., QIAGEN N.V., Quest Diagnostics Incorporated., SOPHiA GENETICS SA, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Gene Fusion Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technique, market is studied across Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Nanostring, NGS Amplicon, and Reverse Transcription Polymerase Chain Reaction (RT-PCR).
  • Based on Indication, market is studied across Haematological Malignacies and Solid Tumors.
  • Based on Application, market is studied across Disease Diagnosis and Research.
  • Based on End User, market is studied across Academic & Research Centers, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer worldwide
      • 5.1.1.2. Increasing genomic and molecular biology reserach
      • 5.1.1.3. Extensive use for discovery of biomarkers
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited accessibility to gene fusion testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Advent of liquid-biopsy based gene fusion testing technologies
      • 5.1.3.2. Inclination towards personalize medicine and targeted therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and dearth of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gene Fusion Testing Market, by Technique

  • 6.1. Introduction
  • 6.2. Fluorescence In Situ Hybridization (FISH)
  • 6.3. Immunohistochemistry (IHC)
  • 6.4. Nanostring
  • 6.5. NGS Amplicon
  • 6.6. Reverse Transcription Polymerase Chain Reaction (RT-PCR)

7. Gene Fusion Testing Market, by Indication

  • 7.1. Introduction
  • 7.2. Haematological Malignacies
  • 7.3. Solid Tumors

8. Gene Fusion Testing Market, by Application

  • 8.1. Introduction
  • 8.2. Disease Diagnosis
  • 8.3. Research

9. Gene Fusion Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Centers
  • 9.3. Hospitals & Diagnostic Laboratories
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Gene Fusion Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Gene Fusion Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Gene Fusion Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amoy Diagnostics Co., Ltd.
  • 2. Arima Genomics, Inc.
  • 3. Biocare Medical, LLC
  • 4. Biocartis NV
  • 5. Caris Life Sciences
  • 6. Danaher Corporation
  • 7. Empire Genomics, Inc.
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Guardant Health, Inc.
  • 10. Illumina, Inc.
  • 11. Integrated DNA Technologies, Inc.
  • 12. Myriad Genetics, Inc.
  • 13. Natera, Inc.
  • 14. NeoGenomics, Inc.
  • 15. OncoDNA SA
  • 16. Paragon Genomics, Inc.
  • 17. QIAGEN N.V.
  • 18. Quest Diagnostics Incorporated.
  • 19. SOPHiA GENETICS SA
  • 20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GENE FUSION TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. GENE FUSION TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENE FUSION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENE FUSION TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NANOSTRING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NGS AMPLICON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HAEMATOLOGICAL MALIGNACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2023